CorMedix Inc. (CRMD)

↓ Download CSV

CIK 0001410098 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, CorMedix Inc. reported revenue of $311.71M, up 617.0% from the prior year. The company was profitable, with a net margin of 52.3% and a gross margin of 88.5%. It held $826.14M in total assets against $420.83M in total liabilities.

Key ratios (FY2025)

88.5%
Gross margin
48.2%
Operating margin
52.3%
Net margin
40.2%
Return on equity
+617.0%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$311.71M$43.47M$65.4K$190.9K$239.2K$283.3K$429.8K$329.3K$224.1K
Cost of Revenue$22.09M$3.03M$3.7K$148.9K$204.8K$373.2K$396.8K$115.0K$366.7K
Gross Profit$275.75M$40.28M$61.7K$42.0K$34.4K-$90.0K$33.0K$214.4K-$142.6K
Operating Income$150.14M-$22.36M-$48.96M-$30.62M-$29.44M-$27.22M-$21.01M-$26.86M-$32.92M-$24.76M
Net Income$163.06M-$17.93M-$46.34M-$29.70M-$28.21M-$22.03M-$16.43M-$26.83M-$33.01M-$24.64M
EPS (Diluted)$2.04$-0.30$-0.91$-0.74$-0.75
Total Assets$826.14M$118.85M$82.06M$62.04M$68.95M$49.31M$29.48M$18.83M$13.45M$21.91M
Total Liabilities$420.83M$34.19M$11.92M$6.98M$6.15M$5.09M$5.83M$13.89M$6.26M$4.09M
Shareholders' Equity$405.31M$84.66M$70.14M$55.06M$62.80M$44.22M$23.65M$4.93M$7.19M$17.81M
Cash & Equivalents$144.84M$40.65M$43.64M$43.15M$53.32M$41.91M$16.35M$17.62M$10.38M$8.06M
Operating Cash Flow$175.05M-$50.62M-$38.41M-$24.36M-$21.16M-$21.97M-$15.05M-$23.70M-$28.59M-$22.27M
Capital Expenditures$2.26M$116.0K$327.3K$219.4K$1.43M$112.6K$36.6K$48.9K$152.0K$58.7K
Shares Outstanding79.26M64.41M54.94M42.82M38.09M33.56M25.67M21.78M71.41M40.43M